Presenter's Information

David Joel Cohen, MD

Country USA
Specialty Interventional Cardiologist
  1. Quality of Life Benefits of Tricuspid Valve Therapies - Insights From the TRILUMINATE Trial
  2. Challenges With Valve-in-Valve TAVR - Role of Bioprosthetic Valve Fracture, Coronary Protection, and Leaflet Modification
  3. PARTNER 3 Low Risk 5 Year Clinical and Echocardiographic Follow-up
  4. Novel Drug-Eluting Stent Designs: Not Yet Plateau, Still Need to Go!!!
  5. Contemporary Best Antiplatelet Strategy in HBR or CHIP Patients: How and What?
  6. Cost-Effectiveness of TEER - Insights From the COAPT Trial
  7. Challenges with ViV TAVR - Role of Bioprosthetic Valve Fracture, Coronary Protection, and Leaflet Modification
  8. Temporal Trends in TAVR Indication and Outcomes - Insights from the US TVT Registry
  9. Optimal Indication for CEP for TAVR: Insights from the STS-TVR and PROTECTED-TAVR
  10. Year-In-Review: Transcatheter Valve Therapy
  11. How Recent Guidelines Will Change the Approach of Mitral Disease Management in the Coming Years
  12. Left Main Revascularization; Consensus and Gaps in 2023
  13. Cost-effectiveness of TMVR (MitraClip)- Insights from the COAPT Trial
  14. Optimal Indication for Cerebral Embolic Protection for TAVR: Insights from the TVT Registry
  15. TAVR Economics and Efficiencies: Insights from the First Decade
  16. Economic Outcomes of TAVR vs SAVR for Low-Risk Patients: Results from the PARTNER 3 Trial
  17. Bioprosthetic Valve Fracture for Optimization of Valve-in-Valve: When, Why, and How?
  18. Composite Outcomes and Net Adverse Events: Implications for Trial Design and Interpretation
  19. COVID-19 and RAAS Inhibitors
  20. Who Should Not Undergo TAVR? Key Insights from the Pivotal Trials and Registries
  21. Quality of Life Outcomes of Transcatheter Mitral Valve Repair: Insights from the COAPT
  22. QOL Outcomes of the COAPT Trial
  23. A Journey of PCSK9 Inhibitors: From Genetics To Clinics
  24. The Emerging Role of NOACs in the Management of Stable CAD and PAD
  25. Failing Bioprosthetic Valves: Valve Fracture, Basilica, and Others
  26. ViV TAVR: The Role of Bioprosthetic Valve Fracture
  27. Valve-in-Valve: TAVR with BVF(Bioprosthetic Valve Fracture): In-Depth Techniques and Updated Data
  28. TAVR: Insights from Quality of Life and Economic Evaluation
  29. Stable CAD & PAD: COMPASS Trial - Will It Change Practice?
  30. PARTNER 2A and SAPIEN 3 Cost-Effectiveness: Cost-effectiveness of TAVR Versus SAVR in Intermediate Risk Patients with Aortic Stenosis
  31. Expanding Role of NOAC in PCI/AF, ACS, and Stable ASCVD: Recent Trials and Next Expectations
  32. Bioprosthetic Valve Fracture for Optimizing the Results of Valve in Valve TAVR
  33. TAVR: Insights from QOL and Economic Evaluation
  34. Selecting the Appropriate Patients for Long-term DAPT; Insights from PEGASUS TIMI-54
  35. ACS and DAPT Duration: Which One and How Long?
  36. TAVR - Year in Review
  37. Finding from PARTNER II Quality of Life Data
  38. What Is the Optimal Duration of DAPT After PCI/DES?
  39. Bioresorbable Vascular Scaffolds and DAPT Duration: The Longer the Better?
  40. Selecting the Appropriate Patients for Long-Term DAPT; Insights from Latest Trials
  41. Extremely High Risk for TAVR - Insights from QOL and Cost-Effectiveness Studies
  42. Optimizing Antiplatelet Therapy: Balancing Ischemic & Bleeding Risks
  43. Pretreatment with P2Y12 Inhibitors: When Selective vs. Routine Is Used?
  44. Cost-Effectiveness and Its Clinical Application
  45. Cost-Effectiveness of PCI for LM Disease
  46. Six Months Enough!
  47. Quality of Life After TAVI: What Do We Know? Why Should You Care?
  48. Guideline Today: Preload Prior to PCI - Standard of Care
  49. Early Insights on Cost-effectiveness
  50. CABG Status 2013: (i) Is Off-pump a Real Option? (ii) Aftermath of FREEDOM Results
  51. Counterpoint: Resisting the Bioabsorbable DES "Bandwagon": A Healthy Dose of Skepticism
  52. Why the Adoption of New Agents Is So Low?
  53. Management Guideline for Ischemic HF
  54. When Is TAVI Not Cost-effective?
  55. How to Overcome the Challenges?: New Agents - Prasugrel
  56. Nuances of Clinical Trials: Trial Size, Power Analysis, Sub Groups
  57. New Thienopyridine Use in ACS and PCI (TRITON-TIMI 38 and Several Subgroup Analyses, PLATO and Several Subgroup Analyses, and CHAMPION Trials)
  58. Cost-Effectiveness of Prasugrel vs. Clopidogrel in ACS
  59. Optimal Dosing of Antiplatelet Therapy in Patients With ACS Undergoing an Early Invasive Strategy: Insight from CURRENT-OASIS7 Trial
  60. Clopidogrel: Current OASIS7 - Double Is Better !!
  61. The Nuances of Superiority and Non-Inferiority Trials: Design Considerations, Choice of Endpoints, Cost Effectiveness Analyses
  62. Randomized Trials vs. Observational Registries: Strengths and Weaknesses
  63. Structural Heart Disease
  64. Updated Antiplatelet Therapy After PCI; Prasugrel, AZD6140..;The Future We Can Expect in Routine Practice?
Conference Slides
Category